
Experience
Hengrui Pharma and GSK Enter Agreement to Develop up to 12 Medicines
July 27, 2025
Cooley advised Hengrui Pharma, a global pharmaceutical company, on its up to $12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline.
Related contacts
Related Practices & Industries
Vicebio to Be Acquired by Sanofi for $1.6 Billion
July 25, 2025
Cooley advised Medicxi and other venture capital investors in Sanofi’s $1.6 billion acquisition of Vicebio, a biopharmaceutical company that develops novel vaccines against life-threatening respiratory viral infections.
Related contacts
Related Practices & Industries
EsoBiotec Announces up to $1 Billion Acquisition by AstraZeneca
March 17, 2025
Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.
Related contacts
Related Practices & Industries
PetLab Co. Announces Majority Stake Sale to BC Partners
February 26, 2025
Cooley advised PetLab Co., a rapidly growing independent pet supplement brand headquartered in London, on its majority stake sale to BC Partners, a top international investment firm.
Related contacts
Related Practices & Industries
DataStax Announces Acquisition by IBM
February 25, 2025
Cooley advised DataStax, an artificial intelligence (AI) and data solution provider, on its acquisition by IBM (NYSE: IBM), a provider of global hybrid cloud and AI solutions and consulting expertise.
Related contacts
Related Practices & Industries
Related news and events
Admissions and credentials
England and Wales, Solicitor
Memberships and affiliations
Chartered Institute of Taxation
Association of Taxation Technicians